Last Updated : May 23, 2025
Details
Generic Name:
mepolizumab
Project Status:
Pending
Therapeutic Area:
chronic obstructive pulmonary disease
Manufacturer:
GlaxoSmithKline Inc.
Call for patient/clinician input open:
Brand Name:
Nucala
Project Line:
Reimbursement Review
Project Number:
SR0888-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Nucala is indicated as add-on maintenance treatment for adult patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Nucala is indicated as add-on maintenance treatment for adult patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : May 23, 2025